Cantor Fitzgerald Predicts TSHA FY2025 Earnings

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) – Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Taysha Gene Therapies in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska anticipates that the company will post earnings of ($0.40) per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $7.00 price objective on the stock. The consensus estimate for Taysha Gene Therapies’ current full-year earnings is ($0.35) per share.

A number of other analysts have also commented on TSHA. Canaccord Genuity Group lifted their target price on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Friday, November 15th. Needham & Company LLC reaffirmed a “buy” rating and set a $6.00 price objective on shares of Taysha Gene Therapies in a research note on Monday, January 6th. JMP Securities reiterated a “market outperform” rating and issued a $5.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Finally, Chardan Capital restated a “buy” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research report on Thursday, November 14th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $6.63.

Taysha Gene Therapies Price Performance

Shares of NASDAQ:TSHA opened at $1.53 on Wednesday. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.51 and a quick ratio of 5.51. The stock has a market cap of $313.56 million, a price-to-earnings ratio of 2.43 and a beta of 0.95. The company has a 50 day moving average of $2.12 and a 200-day moving average of $2.10. Taysha Gene Therapies has a one year low of $1.19 and a one year high of $4.32.

Institutional Trading of Taysha Gene Therapies

Several hedge funds and other institutional investors have recently modified their holdings of the company. Geode Capital Management LLC boosted its position in shares of Taysha Gene Therapies by 23.7% during the third quarter. Geode Capital Management LLC now owns 3,562,758 shares of the company’s stock worth $7,163,000 after buying an additional 682,273 shares during the period. Wellington Management Group LLP acquired a new position in Taysha Gene Therapies during the 3rd quarter worth approximately $931,000. Los Angeles Capital Management LLC acquired a new position in Taysha Gene Therapies during the 3rd quarter worth approximately $416,000. Barclays PLC grew its stake in shares of Taysha Gene Therapies by 356.0% during the 3rd quarter. Barclays PLC now owns 247,280 shares of the company’s stock worth $513,000 after acquiring an additional 193,046 shares in the last quarter. Finally, Rhumbline Advisers acquired a new stake in shares of Taysha Gene Therapies in the second quarter valued at approximately $413,000. Institutional investors and hedge funds own 77.70% of the company’s stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.